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ABSTRACT

Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide. Recently, oral
administration of resveratrol (trans-3,5,4’-trihydroxystilbene), has been reported to significantly
reduce tumor proliferation in colorectal cancer patients, however, with little specific information
on functional connections. The pathogenesis and development of colorectal cancer is a multi-step
process that can be categorized using three phenotypic pathways, respectively, chromosome
instability (CIN), microsatellite instability (MSI) and CpG island methylator (CIMP). Targets of
resveratrol, including a high affinity binding protein, quinone reductase 2 (QR2), have been
identified with little information on disease association. We hypothesize that the relationship
between resveratrol and different CRC etiologies might be gleaned using publicly available
databases. A web-based microarray gene expression data-mining platform, Oncomine, was
selected and used to determine whether QR2 may serve as a mechanistic and functional biotarget
within the various CRC etiologies. We found that QR2 mRNA is overexpressed in CRC
characterized by CIN, particularly in cells showing a positive KRAS (Kirsten rat sarcoma viral
oncogene homolog) mutation, as well as by the MSI but not the CIMP phenotype. Mining of
Oncomine revealed an excellent correlation between QR2 mRNA expression and certain CRC
etiologies. Two resveratrol associated genes, adenomatous polyposis coli (APC) and TP53 found
in CRC were further mined, using cBio portal and Colorectal Cancer Atlas which predicted a
mechanistic link to exist between resveratrol→QR2/TP53→CIN.
Multiple web-based data mining can provide valuable insights which may lead to hypotheses
serving to guide clinical trials and design of therapies for enhanced disease prognosis and patient
survival. This approach resembles a BioGPS, a capability for mining Web-based databases that

can elucidate the potential links between compounds to provide correlations of these interactions
with specific diseases.
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Oncomine is a readily available web-based platform that gives insight into cancer genomics by
providing microarray datasets for different cancers (www.oncomine.org) (Rhodes et al., 2004;
Rhodes et al., 2007). The expression level of the QR2 gene in CRC was analyzed by searching
the Oncomine database. The mRNA expression of QR2 in clinical samples of normal versus
CRC patients and QR2 mRNA expression among different types of CRC were also compared.
The cBio Cancer Genomics Portal (http://cbioportal.org) is a resource for exploring, visualizing,
and analyzing data from multidimensional cancer genomics by reducing molecular profiles
from cancer tissues and cell lines into understandable genetic, epigenetic, gene expression, and
proteomic events. The query interface thus enables researchers to interactively explore genetic
alterations across samples, genes, and pathways. This database (Cerami et al., 2012; Gao et al.,
2013) was used to explore the connectivity of resveratrol associated genes across all CRC studies
available in the databases. The Colorectal Cancer Atlas database (http://www.colonatlas.org) is
an additional open platform accessed by using categorized lists of genes, sequence variations,
cell lines and techniques (Chisanga et al., 2016). The gene information page includes features
such as gene details, domain details, post-translational modifications, protein identification,
sequence variations, pathways and protein-protein interactions. We explored the Colorectal
Cancer Atlas to interactively probe the protein-protein network of resveratrol target QR2.
Combined with Oncomine and the cBio Cancer Genomics Portal, the Colorectal Cancer Atlas

provided the third source for a workflow platform in categorizing molecular mechanisms of
resveratrol and its association with clinical outcomes found in CRC.
Resveratrol has been shown to have chemopreventive effects in CRC and its utility in adjunctive
therapy has been supported by clinical studies (Nguyen et al., 2009; Patel et al., 2010). We
evaluated whether the gene of its high affinity target protein, QR2, can be used to generate
hypotheses regarding chemopreventive efficacies of resveratrol on CRC with varying etiologies.
The Oncomine database revealed that QR2 is correlated with CIN harboring the KRAS mutation;
with statistically significant overexpression of QR2 mRNA occurring in KRAS-mutated
compared to wild type KRAS carcinomas. KRAS (12p12.1) encodes a GTP-binding protein that,
when mutated, can cause a loss of intrinsic GTPase activity and, accordingly, elicits constitutive
signaling through the RAS-RAF-MEK-ERK cascade. Elevated levels of QR2 could conceivably
increase demand for its co-substrate, N-ribosyl nicotinamide ( NRN), by enhancing hydrolysis of
NAD+ or NADP+. Reduction in the levels of NAD+ or NADP+ can result in an enhanced
oxidized cellular environment. High expression of QR2 could also result in increased cellular
levels of oxidized NRN which can cause G1/S cell cycle arrest and inhibit inosine 5’
monophosphate dehydrogenase (Gharehbaghi et al., 1994), an enzyme involved in de novo GTP
biosynthesis. It is however noteworthy that an increased production of guanine nucleotides
occurs in rapidly proliferating cells ultimately affecting the functioning of mutated KRAS. In
addition, since NAD+ functions as the substrate for poly(ADP-ribose) polymerase 1 (PARP-1),
a decrease in its level would diminish formation of poly (ADP-ribosylated) proteins that play key
roles in several nuclear events that include DNA repair, replication, and transcription (Nakamura
et al., 2003; Sauve, 2008). In a broader context, however, most studies listed (Table 1) contain
insufficient details on the CIN pathway to CRC. This limits definitive evaluation of QR2 gene

expression in the CIN pathway for conclusive statements or hypotheses to be reached. The most
pronounced QR2 changes were found in studies by Notterman et al. (2001) which showed an
almost 400% increase in colon adenocarcinoma compared to healthy tissue. The study included
patients from a wide age range (ages 30 to 89), from different races, early to advanced CRCs,
male and female, and TP53 mutations (Table S1). Utilizing Oncomine to distinguish QR2
expression for each of these subgroups, we did not find correlations among QR2 expression and
any of these characteristics. By excluding CIMP-high patients in this study and observing that
the CIN pathway is more commonly found in patients (Table 2), we hypothesize that these QR2
mRNA alterations are correlated with the CIN etiology. However, the putative molecular
determinants that underlie or contribute to the significant increase in QR2 expression in
adenocarcinoma remain to be determined. By contrast, as observed in the top 10% of altered
genes, Skrzypczak et al. (2010) reported a decrease in QR2 expression in epithelial adenoma
compared to that in normal tissue. However, the study included only females, sporadic CRC
cases and used unpaired controls. Gender differences do not play a role in QR2 expression in
CRC, since almost all of the studies identified in Oncomine distinguish between males and
females, but none showed gender differences in QR2 expression. The significance of this study is
limited, however, by small sample size (10 healthy vs. 5 adenoma) and that cancerous tissue was
not paired with adjacent non-involved mucosa.
The Oncomine database is available both as a subscription database and as open access.
Although the free Oncomine version is very useful for generating general hypotheses regarding
specific genes of interest, our analysis was limited by the paucity of gene expression data on
QR2 and the lack of classification in several studies. To further elucidate the molecular
mechanisms of resveratrol and its association with clinical outcomes found in CRC, cBio portal

for Cancer Genomics (http://cbioportal.org) (Cerami et al., 2012; Gao et al., 2013) and
Colorectal Cancer Atlas (Chisanga et al., 2016) were included with Oncomine, building on our
recently introduced functional/activity network (FAN) analysis (Hsieh et al., 2016). Through
systematic query of the publicly available databases, respectively, Oncomine, cBio portal and
Colon Cancer Atlas, we propose that bioefficacy of resveratrol observed in CRC patients
operates by the following pathway: resveratrol→QR2/TP53→CIN pathway (intersected either by
APC↔KRAS or APC↔PIK3CA).
This combined Oncomine-cBio Portal-Colorectal Cancer Atlas workflow platform engenders
three simple steps: (i) identify resveratrol binding target QR2 and its association with the
etiology of CRC using Oncomine (Rhodes et al., 2004; Rhodes et al., 2007), (ii) explore and
verify whether genetic alterations exist for the identified resveratrol-associated genes/proteins
across CRC samples in cancer genomics projects using cBio portal (Cerami et al., 2012; Gao et
al., 2013) and (iii) explore Colorectal Cancer Atlas to interactively probe the protein-protein
network of resveratrol target QR2. To our knowledge, this is a hitherto unexplored strategy that
provides rationale as well as foundation in seeking certainty of biological plausibility.
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